Kopran Ltd
Kopran Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
Target to grow to around INR1,200 crores in the next 3 years through new products and volume increase. Kopran targets revenue growth to around INR 1,200 crores over the next 3 years, driven by new products and increased volumes benefiting from economies of scale.
From Kopran Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Target to grow to around INR1,200 crores in the next 3 years through new products and volume increase.
- Expect 10%-12% growth in API segment next year, and about 20% growth in the following year.
- Consolidated sales growth expected around 15% for FY '26 and 20% for FY '27.
- Expansion in CMO and CDMO projects to contribute significantly; aiming for over 50% of business from these in 2 years.
- Increased market share in key products like Meropenem (around 20% contribution currently).
- Capacity expansions underway at Panoli and Mahad plants to meet increasing demand, with Panoli expected to stabilize next year.
2 more points from Kopran Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Kopran Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- For the next 1 to 2 years, Kopran Limited does not foresee very large capex, except possibly for setting up vial filling for penems.
- Existing capacity is considered sufficient to meet expected demand for the next 2 to 3 years.
- In FY '23 and '24, capex was around INR 60 crores each year; capex is expected to significantly reduce in the next couple of years.
- Additional capex may be needed if existing projects under consideration materialize and demand increases, requiring dedicated plants.
- For formulation businesses, capex remains moderate, around INR 10 crores over 9 months.
2 more points from Kopran Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Kopran Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Kopran Limited currently has 26 CMO and CDMO projects, either near completion or completed.
- Commercial supplies for these projects are expected to start by Q1 FY '26.
- An additional 18 CMO and CDMO projects are under implementation, with commercialization expected in stages between 12 to 24 months.
- These projects involve a mix of existing and new therapeutic areas, some involving site transfers and new product developments.
- The company is entering new CMO and CDMO contracts, aiming to expand this segment further over the next 6 months.
- Focus is on regulated markets including the UK and Canada.
2 more points from Kopran Ltd's call on order book
Pro opens every point from 15K+ earnings calls
Kopran Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹234 Cr, net profit ₹19 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Kopran's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
Kopran Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Kopran Ltd Q3 FY25 results?
Target to grow to around INR1,200 crores in the next 3 years through new products and volume increase. Kopran targets revenue growth to around INR 1,200 crores over the next 3 years, driven by new products and increased volumes benefiting from economies of scale.
What is Kopran Ltd share price analysis?
Kopran Ltd currently shows a neutral. The stock trades at a P/E of 37.1 with a market cap of ₹955 Cr. Investors should review the full earnings analysis for detailed insights.
Is Kopran Ltd planning capital expenditure?
For the next 1 to 2 years, Kopran Limited does not foresee very large capex, except possibly for setting up vial filling for penems.
Keep Kopran Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.